3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Buy
60
HBM Quote, Financials, Valuation and Earnings
Last price:
$7.68
Seasonality move
:
-1.65%
Day range:
$7.28 - $7.66
52-week range:
$6.42 - $10.49
Dividend yield:
0.19%
P/E ratio:
42.17x
P/S ratio:
1.42x
P/B ratio:
1.17x
Volume:
6.7M
Avg. volume:
7.8M
1-year change:
8.43%
Market cap:
$3B
Revenue:
$2B
EPS (TTM):
$0.18
Analysts' Opinion
-
Consensus RatingHudbay Minerals has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.25, Hudbay Minerals has an estimated upside of 74.57% from its current price of $7.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $7.59.
Fair Value
-
According to the consensus of 8 analysts, Hudbay Minerals has 74.57% upside to fair value with a price target of $13.25 per share.
HBM vs. S&P 500
-
Over the past 5 trading days, Hudbay Minerals has underperformed the S&P 500 by -6.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hudbay Minerals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hudbay Minerals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hudbay Minerals reported revenues of $584.9M.
Earnings Growth
-
Hudbay Minerals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hudbay Minerals reported earnings per share of $0.05.
Enterprise value:
3.6B
EV / Invested capital:
--
Price / LTM sales:
1.42x
EV / EBIT:
10.25x
EV / Revenue:
1.79x
PEG ratio (5yr expected):
0.05x
EV / Free cash flow:
11.40x
Price / Operating cash flow:
9.02x
Enterprise value / EBITDA:
4.63x
Gross Profit (TTM):
$553.8M
Return On Assets:
1.42%
Net Income Margin (TTM):
3.8%
Return On Equity:
3.12%
Return On Invested Capital:
2.1%
Operating Margin:
26.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $1.7B | $2B | $602.2M | $584.9M | |
| Gross Profit | $276.9M | $392.5M | $553.8M | $196.7M | $184.4M | |
| Operating Income | $300.9M | $298.2M | $420.4M | $129.6M | $152.2M | |
| EBITDA | $495.2M | $651.3M | $780.9M | $234M | $255.3M | |
| Diluted EPS | $0.26 | $0.20 | $0.18 | $0.10 | $0.05 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $755.7M | $656.7M | $524.2M | $673.2M | $1B | |
| Total Assets | $4.7B | $4.6B | $4.3B | $5.3B | $5.5B | |
| Current Liabilities | $448.8M | $509.2M | $447.6M | $537.4M | $537.2M | |
| Total Liabilities | $3B | $3.1B | $2.8B | $3.1B | $2.8B | |
| Total Equity | $1.7B | $1.5B | $1.6B | $2.2B | $2.6B | |
| Total Debt | $1.1B | $1.2B | $1.2B | $1.3B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $487.8M | $476.9M | $666.2M | $229.1M | $241.9M | |
| Cash From Investing | -$337.7M | -$271.8M | -$382.9M | -$82.6M | -$98.9M | |
| Cash From Financing | -$196.3M | -$182.4M | $10.2M | -$141.8M | -$41.3M | |
| Free Cash Flow | $178.8M | $195.8M | $317.3M | $148.1M | $143.2M | |
HBM
Sector
Market Cap
$3B
$18.4M
Price % of 52-Week High
72.36%
60.93%
Dividend Yield
0.19%
0%
Shareholder Yield
--
1.21%
1-Year Price Total Return
8.43%
-12.67%
Beta (5-Year)
1.620
0.927
Dividend yield:
0.19%
Annualized payout:
$0.01
Payout ratio:
7.17%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$8.07
200-day SMA
Sell
Level
$8.44
Bollinger Bands (100)
Sell
Level
7.74 - 9.1
Chaikin Money Flow
Buy
Level
50.3M
20-day SMA
Sell
Level
$7.70
Relative Strength Index (RSI14)
Sell
Level
45.09
ADX Line
Sell
Level
16.11
Williams %R
Neutral
Level
-66.443
50-day SMA
Sell
Level
$8.08
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
33.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.342)
Sell
CA Score
(Annual)
Level (-0.3429)
Buy
Beneish M-Score
(Annual)
Level (-3.1122)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.5597)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.
Stock Forecast FAQ
In the current month, HBM has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HBM average analyst price target in the past 3 months is $13.25.
-
Where Will Hudbay Minerals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hudbay Minerals share price will rise to $13.25 per share over the next 12 months.
-
What Do Analysts Say About Hudbay Minerals?
Analysts are divided on their view about Hudbay Minerals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hudbay Minerals is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Hudbay Minerals's Price Target?
The price target for Hudbay Minerals over the next 1-year time period is forecast to be $13.25 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HBM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hudbay Minerals is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HBM?
You can purchase shares of Hudbay Minerals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hudbay Minerals shares.
-
What Is The Hudbay Minerals Share Price Today?
Hudbay Minerals was last trading at $7.68 per share. This represents the most recent stock quote for Hudbay Minerals. Yesterday, Hudbay Minerals closed at $7.59 per share.
-
How To Buy Hudbay Minerals Stock Online?
In order to purchase Hudbay Minerals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 18.04% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 8.08% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 15.31% over the past day.
